Michael K Schultz
Overview
Explore the profile of Michael K Schultz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
707
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pretze M, Michler E, Kastner D, Kunkel F, Sagastume E, Schultz M, et al.
EJNMMI Radiopharm Chem
. 2024 Nov;
9(1):81.
PMID: 39604560
Background: Recently, radiotheranostics comprising the true matched radionuclide pair Pb could serve as real dosimetric planning utility using Pb-radiolabelled pharmaceuticals before therapy with Pb-radiolabelled counterparts. Pb might act as the...
2.
Thakral P, Sen I, Das S, Schultz M, Kumari J, Virupakshappa C, et al.
Indian J Nucl Med
. 2024 Jul;
39(2):142-143.
PMID: 38989305
Targeted alpha therapy (TAT) using lead-212 (Pb-212)-labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging...
3.
Gape P, Schultz M, Stasiuk G, Terry S
Pharmaceuticals (Basel)
. 2024 Mar;
17(3).
PMID: 38543120
This review article explores the evolving landscape of Molecular Radiotherapy (MRT), emphasizing Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumours (NETs). The primary focus is on the transition from β-emitting...
4.
Singh N, Rana N, Thakral P, Malik D, Schultz M, Sen I
Clin Nucl Med
. 2024 Mar;
49(6):546-548.
PMID: 38537249
212 Pb emerges as a compelling in vivo α-particle generator for targeted α therapy due to its favorable half-life ( t1/2 = 10.6 hours) aligning with the biological half-lives of...
5.
Li M, Robles-Planells C, Liu D, Graves S, Vasquez-Martinez G, Mayoral-Andrade G, et al.
Eur J Nucl Med Mol Imaging
. 2023 Dec;
51(5):1395-1408.
PMID: 38095674
Purpose: Cancer treatment with alpha-emitter-based radioligand therapies (α-RLTs) demonstrates promising tumor responses. Radiolabeled peptides are filtered through glomeruli, followed by potential reabsorption of a fraction by proximal tubules, which may...
6.
Pretze M, Michler E, Runge R, Wetzig K, Tietze K, Brandt F, et al.
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004470
(1) Background: In neuroendocrine tumors (NETs), somatostatin receptor subtype 2 is highly expressed, which can be targeted by a radioactive ligand such as [Lu]Lu-1,4,7,10-tetraazacyclododecane-,',″,‴,-tetraacetic acid-[Tyr,Thr]-octreotide (Lu-DOTA-TOC) and, more recently, by...
7.
Michler E, Kastner D, Brogsitter C, Pretze M, Hartmann H, Freudenberg R, et al.
Eur J Nucl Med Mol Imaging
. 2023 Nov;
51(5):1490-1492.
PMID: 37991526
No abstract available.
8.
Lee D, Li M, Liu D, Baumhover N, Sagastume E, Marks B, et al.
Eur J Nucl Med Mol Imaging
. 2023 Nov;
51(4):1147-1162.
PMID: 37955792
Purpose: The lead-203 (Pb)/lead-212 (Pb) elementally identical radionuclide pair has gained significant interest in the field of image-guided targeted alpha-particle therapy for cancer. Emerging evidence suggests that Pb-labeled peptide-based radiopharmaceuticals...
9.
Bauer D, Carter L, Atmane M, De Gregorio R, Michel A, Kaminsky S, et al.
J Nucl Med
. 2023 Nov;
65(1):109-116.
PMID: 37945380
Although pancreatic ductal adenocarcinoma (PDAC) is associated with limited treatment options and poor patient outcomes, targeted α-particle therapy (TAT) represents a promising development in the field. TAT shows potential in...
10.
Li M, Robles-Planells C, Liu D, Graves S, Vasquez-Martinez G, Mayoral-Andrade G, et al.
bioRxiv
. 2023 Oct;
PMID: 37808634
Purpose: Cancer treatment with alpha-emitter-based radioligand therapies (α-RLTs) demonstrates promising tumor responses. Radiolabeled peptides are filtered through glomeruli, followed by potential reabsorption of a fraction by proximal tubules, which may...